Filovirus replication: initiation mechanism and role of RNA secondary structures
丝状病毒复制:RNA二级结构的启动机制和作用
基本信息
- 批准号:8771943
- 负责人:
- 金额:$ 8.19万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2014
- 资助国家:美国
- 起止时间:2014-08-05 至 2016-07-31
- 项目状态:已结题
- 来源:
- 关键词:AdoptedAntiviral AgentsCase Fatality RatesCellsComplexContainmentDataDemocratic Republic of the CongoDevelopmentDiseaseEventFamilyFilovirusGenetic TranscriptionGenomeGenomicsHumanInfectionKnowledgeLife Cycle StagesMapsMessenger RNAModelingMolecularMutationNucleotidesParamyxovirusPolymerasePositioning AttributePrimer ExtensionPromoter RegionsRNARNA VirusesRNA-Directed RNA PolymeraseReplication InitiationResearchRespiratory syncytial virusRhabdoviridaeRoleSiteStructureSystemTechniquesTestingTherapeuticVesicular stomatitis Indiana virusViralViral GenomeViral Hemorrhagic FeversVirionVirusWorkbasedesigndrug developmentmemberpathogenpreventpromoterprototypepublic health relevanceresearch studystemviral RNA
项目摘要
DESCRIPTION (provided by applicant): Ebolaviruses (EBOV) belong to the group of nonsegmented negative-sense (NNS) RNA viruses and are highly pathogenic in humans. Currently, there are no approved therapeutics to treat or prevent EBOV hemorrhagic fever. Ebolaviruses use an RNA-dependent RNA polymerase to replicate and transcribe their genomes. Little is known about the molecular mechanisms employed by the EBOV polymerase to interact with the RNA template and initiate replication. Viral polymerases are common targets for antiviral drug development, and rational design of antiviral compounds targeting viral polymerases requires a thorough understanding of the molecular events involved in genome replication. Here, we propose to dissect the molecular mechanisms used by EBOV to initiate replication. Our preliminary data suggest that EBOV has evolved a replication initiation mechanism that is different from those used by other NNS RNA viruses. According to our model, EBOV initiates replication at position +2 of the template strand and uses an RNA secondary structure adopted by the promoter region to maintain its genome ends. To test this model, we will use RNA isolated from EBOV-infected cells or virions to determine the 3' and 5' ends of the replication products. By mapping the terminal nucleotides of intracellular and virion-associated viral RNA, we will identify the replication start sites. We will further use EBOV minigenome systems to introduce mutations in relevant regions and analyze the effects on replication initiation and genome integrity. We will perform the initial experiments using the EBOV prototype Zaire ebolavirus. We will then analyze if the identified replication mechanism used by ZEBOV is conserved among other EBOV species. Finally, we will determine the role of an RNA secondary structure adopted by the EBOV promoter region for promoter function and replication initiation. Overall, the proposed work will elucidate if the EBOV polymerase has acquired unique capabilities to interact with the viral genome or if it follows a general mechanism shared with other NNS RNA viruses.
描述(由申请人提供):埃博拉病毒(EBOV)属于非节段负义(NNS) RNA病毒群,对人类具有高致病性。目前,没有批准的治疗或预防EBOV出血热的药物。埃博拉病毒使用依赖RNA的RNA聚合酶来复制和转录其基因组。关于EBOV聚合酶与RNA模板相互作用并启动复制的分子机制知之甚少。病毒聚合酶是抗病毒药物开发的常见靶点,针对病毒聚合酶的抗病毒化合物的合理设计需要对基因组复制的分子事件有透彻的了解。在这里,我们建议剖析EBOV启动复制的分子机制。我们的初步数据表明,EBOV已经进化出一种不同于其他NNS RNA病毒的复制启动机制。根据我们的模型,EBOV在模板链的+2位置启动复制,并使用启动子区域采用的RNA二级结构来维持其基因组末端。为了测试该模型,我们将使用从感染ebov的细胞或病毒粒子中分离的RNA来确定复制产物的3‘和5’端。通过绘制细胞内和病毒粒子相关病毒RNA的末端核苷酸,我们将确定复制起始位点。我们将进一步利用EBOV小基因组系统在相关区域引入突变,并分析对复制起始和基因组完整性的影响。我们将使用扎伊尔埃博拉病毒原型进行初步实验。然后,我们将分析ZEBOV所使用的复制机制是否在其他EBOV物种中保守。最后,我们将确定EBOV启动子区域采用的RNA二级结构在启动子功能和复制起始中的作用。总的来说,拟议的工作将阐明EBOV聚合酶是否获得了与病毒基因组相互作用的独特能力,或者是否遵循与其他NNS RNA病毒共享的一般机制。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Elke C Muhlberger其他文献
Elke C Muhlberger的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Elke C Muhlberger', 18)}}的其他基金
Elucidating the immune response of Schreiber's bats to Lloviu virus infection in vitro and in vivo
阐明施赖伯蝙蝠对 Lloviu 病毒感染的体外和体内免疫反应
- 批准号:
10458900 - 财政年份:2022
- 资助金额:
$ 8.19万 - 项目类别:
Elucidating the immune response of Schreiber's bats to Lloviu virus infection in vitro and in vivo
阐明施赖伯氏蝙蝠对 Lloviu 病毒感染的体外和体内免疫反应
- 批准号:
10579294 - 财政年份:2022
- 资助金额:
$ 8.19万 - 项目类别:
Filovirus replication: initiation mechanism and role of RNA secondary structures
丝状病毒复制:RNA二级结构的启动机制和作用
- 批准号:
8904599 - 财政年份:2014
- 资助金额:
$ 8.19万 - 项目类别:
Early Host Immune Response in Protection Against Filovirus Infection
预防丝状病毒感染的早期宿主免疫反应
- 批准号:
8474594 - 财政年份:2009
- 资助金额:
$ 8.19万 - 项目类别:
Early Host Immune Response in Protection Against Filovirus Infection
预防丝状病毒感染的早期宿主免疫反应
- 批准号:
8099009 - 财政年份:2009
- 资助金额:
$ 8.19万 - 项目类别:
Early Host Immune Response in Protection Against Filovirus Infection
预防丝状病毒感染的早期宿主免疫反应
- 批准号:
7680508 - 财政年份:2009
- 资助金额:
$ 8.19万 - 项目类别:
Early Host Immune Response in Protection Against Filovirus Infection
预防丝状病毒感染的早期宿主免疫反应
- 批准号:
8277871 - 财政年份:2009
- 资助金额:
$ 8.19万 - 项目类别:
Early Host Immune Response in Protection Against Filovirus Infection
预防丝状病毒感染的早期宿主免疫反应
- 批准号:
7864186 - 财政年份:2009
- 资助金额:
$ 8.19万 - 项目类别:
相似海外基金
Development of a new generation of antiviral agents that are effective against drug-resistant viruses and prevent serious illness and sequelae.
开发新一代抗病毒药物,可有效对抗耐药病毒并预防严重疾病和后遗症。
- 批准号:
23K18186 - 财政年份:2023
- 资助金额:
$ 8.19万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
A versatile structure-based therapeutic platform for development of VHH-based antitoxin and antiviral agents
一个多功能的基于结构的治疗平台,用于开发基于 VHH 的抗毒素和抗病毒药物
- 批准号:
10560883 - 财政年份:2023
- 资助金额:
$ 8.19万 - 项目类别:
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
- 批准号:
10730692 - 财政年份:2021
- 资助金额:
$ 8.19万 - 项目类别:
Design and synthesis of nucleosides to develop antiviral agents and oligonucleotide therapeutics
设计和合成核苷以开发抗病毒药物和寡核苷酸疗法
- 批准号:
21K06459 - 财政年份:2021
- 资助金额:
$ 8.19万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
- 批准号:
10189880 - 财政年份:2021
- 资助金额:
$ 8.19万 - 项目类别:
Computer-aided identification and synthesis of novel broad-spectrum antiviral agents
新型广谱抗病毒药物的计算机辅助鉴定和合成
- 批准号:
2404261 - 财政年份:2020
- 资助金额:
$ 8.19万 - 项目类别:
Studentship
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
- 批准号:
10222540 - 财政年份:2020
- 资助金额:
$ 8.19万 - 项目类别:
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
- 批准号:
10669717 - 财政年份:2020
- 资助金额:
$ 8.19万 - 项目类别:
Association between sedentary lifestyle and liver cancer development in hepatitis C patients treated with direct-acting antiviral agents
接受直接抗病毒药物治疗的丙型肝炎患者久坐的生活方式与肝癌发展之间的关系
- 批准号:
20K10713 - 财政年份:2020
- 资助金额:
$ 8.19万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
- 批准号:
10174522 - 财政年份:2020
- 资助金额:
$ 8.19万 - 项目类别:














{{item.name}}会员




